Anti-thrombotic effects of selective estrogen receptor modulator tamoxifen

Thrombosis and Haemostasis

Volumn 106, Issue 4, 2011, Pages 624-635

  Nayak, Manasa K ^a   Singh, Sunil K ^a   Roy, Arnab ^a   Prakash, Vivek ^a   Kumar, Anand ^a   Dash, Debabrata ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Antiplatelet drug; Estrogen receptor; Platelet aggregation; Selective estrogen receptor modulators (SERM); Thrombosis

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM ION; COLLAGEN; DIMETHYL SULFOXIDE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TYROSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTITHROMBOTIC ACTIVITY; ARTERY INJURY; ARTERY THROMBOSIS; ARTERY WALL; ARTICLE; BLEEDING TIME; CALCIUM CELL LEVEL; CELL SPREADING; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SHEAR STRESS; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; THROMBOCYTE SPREADING;

ANIMALS; ARTERIOLES; BLEEDING TIME; BLOOD PLATELETS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; HUMANS; MICE; MICROSCOPY, VIDEO; PLATELET AGGREGATION; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TAMOXIFEN; THROMBOSIS;

EID: 80053190899     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-03-0178     Document Type: Article

References (69)

1. MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 1998; 50: 151-196.
2. Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2003; 2: 205-213.
3. Wiseman H, Paganga G, Rice-Evans C, et al. Protective actions of tamoxifen and 4-hydroxytamoxifen against oxidative damage to human low-density lipoproteins: a mechanism accounting for the cardioprotective action of tamoxifen. Biochem J 1993; 292: 635-638.
4. Medina PD, Payre BL, Bernad J, et al. Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells. J Pharmacol Exp Ther 2004; 308: 1165-1173.
5. Furr BJ, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984; 25: 127-205.
6. Grainger DJ, Metcalfe JC. Tamoxifen: teaching an old drug new tricks? Nat Med 1996; 2: 381-385.
7. Park WC, Jordan VC. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention. Trends Mol Med 2002; 8: 82-88.
8. Jordan VC. The only true antiestrogen is no estrogen. Mol Cell Endocrinol 1990; 74: C91-C95.
9. Wiseman H. Tamoxifen as an antioxidant and cardioprotectant. Biochem Soc Symp 1995; 61: 209-219.
10. Stocker R, Keaney JFJ. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381-1478.
11. Zarate CAJ, Singh JB, Carlson PJ, et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord 2007; 9: 561-570.
12. Couldwell WT, Hinton DR, Surnock AA, et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 1996; 2: 619-622.
13. Robins HI, Won M, Seiferheld WF, et al. Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021. Neuro Onco 2006; 8: 47-52.
14. Mastronardi L, Puzzilli F, Ruggeri A, Tamoxifen as a potential treatment of glioma. Anticancer Drugs 1998; 9: 581-586.
15. Subramaniam M, Frenette PS, Saffaripour S, et al. Defects in hemostasis in P-selectin- deficient mice. Blood 1996; 87: 1238-1242.
16. Denis C, Methia N, Frenette PS, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci USA 1998; 95: 9524-9529.
17. Vollmar B, Schmits R, Kunz D, et al. Lack of in vivo function of CD31 in vascular thrombosis. Thromb Haemost 2001; 85: 160-164.
18. Chang Y, Lee JJ, Chen WF, et al. A novel role for tamoxifen in the inhibition of human platelets, Transl Res 2011; 157: 81-91.
19. Grey AB, Evans MC, Kyle C, et al. The anti-oestrogen tamoxifen produces haemodilution in normal postmenopausal women. J Intern Med 1997; 242: 383-388.
20. Vitseva O, Flockhart DA, Jin Y, et al. The effects of tamoxifen and its metabolites on platelet function and release of reactive oxygen intermediates. J Pharmacol Exp Ther 2005; 312: 1144-1150.
21. Nayak M K, Kumar K, Dash D. Regulation of proteasome activity in activated human platelets. Cell Calcium 2011; 49: 228-232.
22. Shrivastava S, Bera T, Singh S K, et al. Characterization of novel anti-platelet properties of silver nanoparticles. ACS Nano 2009; 3: 1357-1364.
23. Jeske WP, Walenga JM, Szatkowski E, et al. Effect of glycoprotein IIb/IIIa antagonists on the HIT seruminduced activation of platelets. Thromb Res 1997; 88: 271-281.
24. Shankey TV, Jeske WP, Walenga JM, Flow cytometric analysis of platelets and platelet function. In: Immunophenotyping Wiley, New York, 2000 pp. 333-359.
25. Dash D, Rao GRK, et al. Characterization of the effects of propranolol on the physical state of platelet membrane. Arch Biochem Biophys 1990; 276: 343-347.
26. May F, Hagedorn I, Pleines I, et al. CLEC-2 is an essential platelet activating receptor in hemostasis and thrombosis. Blood 2009; 114: 3464-3472.
27. Flaumenhaft R, Dilks JR, Rozenvayn R, et al. The actin cytoskeleton differentially regulates platelet α-granule and dense-granule secretion. Blood 2005; 105: 3879-3887.
28. Dvorak AM. Monograph: Procedural guide to specimen handling for the ultrastructural pathology service laboratory. J Electron Microsc Technol 1987; 6: 255-301.
29. Lee KH, Ward BA, Desta Z, et al. Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 791: 245-253.
30. Dobrydneva Y, Weatherman RV, Trebley JP, et al. Tamoxifen stimulates calcium entry into human Platelets. J Cardiovasc Pharmacol 2007; 50: 380-390.
31. Shattil SJ, Hoxie JA, Cunningham M, et al. Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. J Biol Chem 1985; 260: 11107-11114.
32. Hantgan RR, Taylor RG, Lewis JC. Platelets interact with fibrin only after activation. Blood 1985; 65: 1299-1311.
33. Ono A, Westein E, Hsiao S, et al. Identification of a fibrin independent platelet contractile mechanism regulating primary hemostasis and thrombous growth. Blood 2008; 112: 90-99.
34. 3 molecules. Blood 2004; 104: 3979-3985.
35. Khetawath G, Faraday N, Nealen ML, et al. Human megakaryocytes and platelets contain the estrogen receptor β and androgen receptor (AR): testosterone regulates AR expression. Blood 2000; 95: 2289-2296.
36. Jayachandran M, Miller VM. Human platelets contain estrogen receptor a, caveolin- 1 and estrogen receptor associated proteins. Platelets 2003; 14: 75-81.
37. Gronemeyer H, Gustafsson JA, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discovery 2004; 3: 950-964.
38. Pettersson K, Delaunay F, Gustafsson JA. Estrogen receptor beta acts as a dominant regulator of estrogen. Oncogene 2000; 43: 4970-4978.
39. Hall JM, McDonnell DP. The estrogen receptor beta isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999; 140: 5566-5578.
40. Kushner PJ, Agard D, Feng WJ, et al. Oestrogen receptor function at classical and alternative response elements. Novartis Found Symp 2000; 230: 20-26.
41. Migliaccio A, Castoria G, Di Domenico M, et al. Steroid-induced androgen receptoroestradiol receptor β-Src complex triggers prostate cancer cell proliferation. EMBO J 2000; 19: 5406-5417.
42. Lu Q, Pallas DC, Surks HK, et al. Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor α. Proc Natl Acad Sci USA 2004; 101: 17126-17131.
43. Leng X, Zhang W, Nieswandt B, et al. Effects of estrogen replacement therapies on mouse platelet function and glycoprotein VI levels. Circ Res 2005; 97: 415-417.
44. Moro L, Reineri S, Piranda D, et al. Nongenomic effects of 17β estradiol in human platelets: potentiation of thrombin-induced aggregation through estrogen receptor β and Src kinase, Blood 2005; 105: 115-121.
45. Kansra S, Yamagata S, Sneade L, et al. Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol 2005; 239: 27-36.
46. Lam L, Hu X, Aktary Z, et al. Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERα. Breast Cancer Res Treat 2009; 118: 605-621.
47. Merciera I, Maderc S, Calderone A. Tamoxifen and ICI 182,780 negatively influenced cardiac cell growth via an estrogen receptor-independent mechanism. Cardiovasc Res 2003; 59: 883-892.
48. Gagliardi A, Collins DC. Inhibition of angiogenesis by antiestrogens. Cancer Res 1993; 53: 533-535.
49. MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 1998; 50: 151-196.
50. Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2003; 2: 205-213.
51. Grainger DJ, Peter MS. Tamoxifen for the prevention of myocardial infarction in humans: preclinical and early clinical evidence. Circulation 2005; 112: 3018-3024.
52. Kaiser-Kupfer MI, Lippman ME. Tamoxifen retinopathy. Cancer Treat Rep 1978; 62: 315-320
53. Braithwaite RS, Chlebowski RT, Lau J, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003; 18: 937-947.
54. Goldhaber SZ. Tamoxifen: preventing breast cancer and placing the risk of deep vein thrombosis in perspective. Circulation 2005; 111: 539-541.
55. Weitz IC, Israel VK, Liebman HA. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer 1997; 79: 2024-2027.
56. 2+-dependent Binding of Tamoxifen to Calmodulin Isolated from Bovine Brain. Cancer Res 1990; 50: 2753-2758.
57. O'Brien CA, Liskamp RM, Soloman DH, et al. Triphenylenes: a new class of protein kinase C inhibitors. J Natl Cancer 1986; 76: 1243-1246.
58. Kiss Z. Tamoxifen stimulates phospholipase D activity by an estrogen receptor-independent mechanism. FEBS Lett 1994; 355: 173-177.
59. Kedjouar B, de Medina P, Oulad-Abdelghani M, et al. Molecular characterization of the microsomal tamoxifen binding Site. J Biol Chem 2004; 279: 34048-34061.
60. 2+ movement in Chinese hamster ovary (CHO-K1) cells. Arch Toxicol 2003; 7: 160-166.
61. 2+ movement in human osteosarcoma cells. Pharmacol Toxicol 2002; 91: 34-39.
62. Zamaraeva M, Charishnikova O, Saidkhodjaev A, et al. Calcium mobilization by the plant estrogen ferutinin does not induce blood platelet aggregation. Pharmacol Rep 2010; 62: 1117-1126.
63. Lam HYP. Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Commun 1984; 118: 27-32.
64. McClay EF, McClay MT, Monroe L, et al. A Phase II study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma. Melanoma Res 2001; 11: 309-313.
65. Bashey A, Corringham S, Garrett J, et al. A phase II study of two cycles of highdose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle. Bone Marrow Transplant 2000; 25: 519-524.
66. Trump D L, Smith DC, Ellis PG, et al. High-dose oral tamoxifen, a potential multidrug- resistance-reversal agent: Phase I trial in combination with vinblastine. J Natl Cancer Inst 1992; 84: 1811-1816.
67. Choi JS, Kang KW. Enhanced tamoxifen bioavailability after oral administration of tamoxifen in rats pretreated with naringin. Arch Pharm Res 2008; 31: 1631-1636.
68. Yao JC, Thomakos N, McLaughlin P, et al. Tamoxifen-induced thrombocytopenia. Am J Clin Oncol 1999; 22: 529-532.
69. Colditz GA, Willett WC, Stampfer JJ, et al. Menopause and the risk for coronary heart disease in women. N Engl J Med 1987; 316: 1105-1110.